Weil has advised Shanghai Pharmaceuticals, one of China’s largest pharmaceutical groups and dual-listed in both Shanghai and Hong Kong, in its acquisition of Cardinal Health’s pharmaceutical and medical products distribution business in China. The transaction, which followed a highly competitive auction process, is valued at $1.2 billion and is expected to close by the end of the second quarter of 2018, subject to regulatory clearance and other closing conditions.

The Weil team advising Shanghai Pharmaceuticals was led by Corporate partner and China Head Charles Ching, with an integrated Shanghai, Beijing and Hong Kong-based team that includes Corporate associates Jian Liu, Kris Desrosiers, Kevin Wang and Shujie Zhang.